Evidence map›Paper›PMID 41800254›Full record

ArticleInternational journal of biological sciences2026

ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition.

Li-Jie Chen, Changxiang Shi, Eun Ju Yang, Guowen Ren, Shishi Tao, Yue Pu, Xiumei Zhang, Xin Shen, Changjie Wu, Joong Sup Shim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Jie ChenCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Changxiang ShiNanjing Key Laboratory of Female Fertility Preservation and Restoration, Nanjing Women and Children's Healthcare Institute, Women's Hospital of Nanjing Medical University (Nanjing Women and Children's Healthcare Hospital), Nanjing, 210004, China.
Eun Ju YangCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Guowen RenCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Shishi TaoCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Yue PuCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Xiumei ZhangCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Xin ShenCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Changjie WuGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Joong Sup ShimCancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ARID1A, a key component of the SWI/SNF chromatin remodeling complex, is a tumor suppressor frequently inactivated in many cancer types, including endometrial cancer. Exploiting ARID1A deficiency has emerged as a therapeutic strategy in these types of cancer. We here employed a synthetic lethal drug screen for ARID1A and found that JAK/STAT3 pathway is a therapeutic vulnerability in ARID1A-deficient endometrial cancer. Inhibition of JAK/STAT3 selectively inhibited the growth of ARID1A deficient endometria cancer cells

Indexed as

DNA-Binding ProteinsEndometrial NeoplasmsJanus KinasesOncostatin MSTAT3 Transcription FactorTranscription FactorsAnimalsCell Line, TumorFemaleHumansMiceSignal TransductionARID1A protein, humanDNA-Binding ProteinsJanus KinasesOncostatin MSTAT3 Transcription FactorTranscription FactorsARID1Aendometrial cancerOSM/STAT3/PLK1 axissynthetic lethality

Identifiers

PMID41800254
PMCPMC12965241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.